Smith & Nephew (SNN) Lowered to Hold at HSBC
HSBC downgraded shares of Smith & Nephew (NYSE:SNN) from a buy rating to a hold rating in a research report released on Tuesday morning, The Fly reports.
SNN has been the topic of a number of other reports. UBS Group cut shares of Smith & Nephew from a buy rating to a neutral rating in a research note on Wednesday, August 8th. Zacks Investment Research upgraded shares of Smith & Nephew from a sell rating to a hold rating in a research note on Tuesday, August 7th. Finally, Canaccord Genuity restated a buy rating and set a $42.00 price objective on shares of Smith & Nephew in a research note on Monday, August 6th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. The stock has an average rating of Hold and an average target price of $41.00.
Shares of NYSE SNN opened at $33.85 on Tuesday. Smith & Nephew has a fifty-two week low of $33.64 and a fifty-two week high of $39.85. The company has a current ratio of 2.13, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The stock has a market cap of $14.84 billion, a P/E ratio of 17.82, a P/E/G ratio of 2.79 and a beta of 0.47.
About Smith & Nephew
Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.
Read More: Why do earnings reports matter?
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.